We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-2.73%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$535M
AUM Growth
-$66.7M
Cap. Flow
+$12.3M
Cap. Flow %
2.29%
Top 10 Hldgs %
59.08%
Holding
57
New
9
Increased
13
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
SMLR
Semler Scientific
SMLR
+$28.5M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$4.22M
3
KROS icon
Keros Therapeutics
KROS
+$4.18M
4
FOLD
Amicus Therapeutics
FOLD
+$3.28M
5
CMRX
Chimerix, Inc.
CMRX
+$2.75M

Top Sells

Rank Stock Value
1
EPIX
ESSA Pharma
EPIX
+$8.12M
2
MCRB icon
Seres Therapeutics
MCRB
+$5.96M
3
WGS icon
GeneDx Holdings
WGS
+$5.24M
4
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$3.82M
5
KZR
Kezar Life Sciences
KZR
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 99.64%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
26
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$6.98M 1.3%
205,381
– –
TELA icon
27
TELA Bio
TELA
$29.2M
$6.05M 1.13%
443,199
+2,734
+0.6% +$38.1K
PTGX icon
28
Protagonist Therapeutics
PTGX
$9.67B
$5.85M 1.09%
330,222
– –
AFIB
29
DELISTED
Acutus Medical Inc
AFIB
$5.22M 0.97%
590,000
-9,990
-2% -$131K
OPTN
30
DELISTED
OptiNose
OPTN
$4.68M 0.87%
103,900
+22,127
+27% +$928K
LITS
31
Lite Strategy Inc
LITS
$34M
$4.32M 0.81%
78,250
– –
FMTX
32
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$4.24M 0.79%
182,950
+11,950
+7% +$283K
SRRA
33
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.63M 0.68%
165,778
+278
+0.2% +$5.56K
AVTX icon
34
Avalo Therapeutics
AVTX
$1.08B
$3.18M 0.59%
507
-37
-7% -$300K
FOLD
35
DELISTED
Amicus Therapeutics
FOLD
$3.06M 0.57%
+320,800
New +$3.28M
AVEO
36
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.82M 0.53%
455,600
-191,400
-30% -$1.14M
MRUS
37
DELISTED
Merus
MRUS
$2.21M 0.41%
+100,250
New +$2.15M
VIRX
38
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.07M 0.39%
258,556
+1,367
+0.5% +$13.5K
SIOX
39
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.07M 0.39%
955,000
-1,045,000
-52% -$2.27M
CYPH
40
Cypherpunk Technologies Inc
CYPH
$204M
$1.91M 0.36%
47,600
-6,400
-12% -$120K
DTIL icon
41
Precision BioSciences
DTIL
$232M
$1.89M 0.35%
+5,463
New +$1.85M
WHWK
42
Whitehawk Therapeutics
WHWK
$278M
$1.32M 0.25%
+45,020
New +$1.37M
NCNA
43
NuCana
NCNA
$6.12M
$1.24M 0.23%
+96
New +$1.13M
APTO
44
DELISTED
Aptose Biosciences, Inc.
APTO
$1.2M 0.22%
1,220
-958
-44% -$1.2M
AKBA icon
45
Akebia Therapeutics
AKBA
$260M
$897K 0.17%
+311,300
New +$889K
RNAC icon
46
Cartesian Therapeutics
RNAC
$302M
$441K 0.08%
+3,533
New +$427K
CBAY
47
DELISTED
Cymabay Therapeutics
CBAY
$420K 0.08%
+115,015
New +$453K
BLRX
48
BioLineRX
BLRX
$12.1M
$46K 0.01%
417
– –
CDTX
49
DELISTED
Cidara Therapeutics
CDTX
– –
-3,668
Closed -$148K
CRDF icon
50
Cardiff Oncology
CRDF
$76.7M
– –
-463,000
Closed -$3.08M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2021 Portfolio in Review

As of Q3 2021, Opaleye Management held 57 positions worth $535M, down 11% from $602M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management's Q3 2021 filing shows 9 new, 13 increased, 14 reduced and 9 closed positions. Its largest new stake was Semler Scientific: 225,566 shares worth $28.2M. The largest sale was ESSA Pharma, an estimated $8.12M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Opaleye Management's largest Q3 2021 buy was Semler Scientific: 225,566 shares worth $28.2M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q3 2021, an estimated $4.22M increase.
  • Opaleye Management's biggest Q3 2021 reduction was Eton Pharmaceutcials, cutting an estimated $3.14M.
  • Opaleye Management fully exited ESSA Pharma in Q3 2021, selling an estimated $8.12M.
  • Opaleye Management's ten largest holdings make up 59% of its $535M portfolio in Q3 2021.
  • Opaleye Management opened 9 new positions and closed 9 in Q3 2021.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $535M.

Based on Opaleye Management's 13F filing for Q3 2021, filed 16 Nov 2021.